Everolimus-Associated Stomatitis in a Patient Who Had Renal Transplant.

Alessandro Villa, Y. D. Ji, A. Aboalela

Research output: Contribution to journalArticlepeer-review

Abstract

Everolimus is used as an immunosuppressant in renal allograft transplant rejection and in metastatic breast cancer treatment. One side effect of everolimus is stomatitis, referred to as mammalian target of rapamycin inhibitor-associated stomatitis. This side effect can affect treatment course and contribute to discontinuation of therapy or dose reduction, previously reported in the treatment of metastatic breast cancer. Here, we present a case of everolimus-associated stomatitis with a novel management method with intralesional triamcinolone that allows for continuous course of everolimus.
Original languageAmerican English
JournalBMJ Case Reports
DOIs
StatePublished - Oct 2016

Keywords

  • Everolimus-Associated Stomatitis
  • Patient
  • Renal Transplant

Disciplines

  • Medicine and Health Sciences

Cite this